Share Price and Basic Stock Data
Last Updated: February 1, 2026, 9:41 pm
| PEG Ratio | 1.23 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Venus Remedies Ltd operates within the pharmaceuticals sector, with its stock currently priced at ₹745 and a market capitalization of ₹994 Cr. The company has demonstrated fluctuating sales performance over recent quarters, reporting sales of ₹140 Cr in September 2022, which declined to ₹95 Cr by June 2023, before rebounding to ₹168 Cr in September 2023. This trend continued with subsequent quarterly sales reaching ₹143 Cr in December 2023 and ₹195 Cr in March 2024. For the trailing twelve months (TTM), total sales stood at ₹702 Cr. The company’s historical annual sales peaked at ₹597 Cr in March 2022 but slightly dipped to ₹552 Cr in March 2023. The revenue trajectory displays volatility, yet a recovery trend emerged in the latter part of 2023, indicating potential for growth as the company adapts to market conditions.
Profitability and Efficiency Metrics
Venus Remedies reported a net profit of ₹70 Cr, translating to a price-to-earnings (P/E) ratio of 15.7, which falls within a reasonable range compared to industry averages. The operating profit margin (OPM) stood at 16%, reflecting the company’s ability to maintain profitability amidst varying sales figures. In the latest quarter, the OPM was reported at 11%. The return on equity (ROE) was recorded at 7.16%, while the return on capital employed (ROCE) was 11.1%. These profitability metrics indicate that Venus Remedies is managing its operational efficiency effectively, albeit with room for improvement. The interest coverage ratio (ICR) is an impressive 1291.82x, showcasing the company’s strong ability to cover its interest obligations without financial strain, thus reflecting sound operational management.
Balance Sheet Strength and Financial Ratios
The balance sheet of Venus Remedies reveals a robust position, with total reserves amounting to ₹581 Cr against minimal borrowings of ₹14 Cr. This highlights a conservative capital structure, evidenced by a total debt-to-equity ratio of 0.00, indicating no reliance on debt financing. The current ratio of 3.31 suggests strong liquidity, enabling the company to meet its short-term obligations comfortably. The price-to-book value (P/BV) ratio stands at 0.71x, indicating that the stock is trading below its book value, potentially presenting a buying opportunity for investors. Efficiency ratios further illustrate the company’s operational prowess, with a cash conversion cycle of just 72 days, suggesting that the company effectively manages its inventory and receivables to generate cash flow.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Venus Remedies indicates a stable promoter holding of 41.76%, which signifies strong insider confidence in the company’s future. Foreign institutional investors (FIIs) hold 1.86% of the shares, showing limited foreign interest, while domestic institutional investors (DIIs) represent a minor share at 0.75%. The public holds the majority at 55.62%, which reflects broad retail investor participation. However, the gradual decline in the number of shareholders from 22,243 in December 2022 to 17,725 in September 2025 may raise concerns regarding investor sentiment. This trend may suggest that while existing investors remain committed, attracting new investors could be challenging, potentially impacting liquidity and market perception.
Outlook, Risks, and Final Insight
Looking ahead, Venus Remedies faces both opportunities and challenges. The recent recovery in sales and profitability metrics presents a positive outlook, yet the company must navigate market volatility and competition within the pharmaceuticals sector. Key risks include potential fluctuations in raw material costs and regulatory changes that could impact profitability. The company’s ability to sustain its operational efficiency and improve margins will be crucial for future growth. Additionally, the relatively low institutional ownership may limit support during market corrections. Overall, Venus Remedies has a solid foundation, but its future performance will depend on strategic initiatives to enhance market share and investor engagement in a competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 119 Cr. | 94.7 | 195/84.3 | 26.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,538 Cr. | 325 | 479/192 | 73.3 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.8 Cr. | 46.9 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 71.8 Cr. | 49.0 | 49.7/17.0 | 171 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,449.33 Cr | 1,087.86 | 46.53 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 140 | 117 | 156 | 95 | 168 | 143 | 195 | 109 | 170 | 177 | 195 | 137 | 193 |
| Expenses | 127 | 109 | 131 | 85 | 150 | 131 | 176 | 97 | 163 | 158 | 166 | 122 | 162 |
| Operating Profit | 13 | 8 | 25 | 10 | 18 | 12 | 19 | 11 | 8 | 18 | 29 | 15 | 31 |
| OPM % | 9% | 7% | 16% | 11% | 11% | 8% | 10% | 10% | 4% | 10% | 15% | 11% | 16% |
| Other Income | 2 | 4 | 3 | 2 | 3 | 2 | 4 | 2 | 8 | 12 | 7 | 3 | 2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 9 | 7 | 8 | 8 | 6 | 7 | 6 | 6 | 6 | 5 | 5 | 6 | 6 |
| Profit before tax | 6 | 5 | 20 | 5 | 14 | 8 | 17 | 7 | 9 | 25 | 31 | 13 | 26 |
| Tax % | 8% | 28% | 44% | 77% | 31% | 12% | 40% | 82% | 61% | 21% | 32% | 24% | 24% |
| Net Profit | 5 | 3 | 11 | 1 | 10 | 7 | 11 | 1 | 4 | 20 | 21 | 10 | 20 |
| EPS in Rs | 3.99 | 2.46 | 8.27 | 0.88 | 7.44 | 5.12 | 7.86 | 0.91 | 2.63 | 14.66 | 15.71 | 7.18 | 15.06 |
Last Updated: December 28, 2025, 3:02 pm
Below is a detailed analysis of the quarterly data for Venus Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 193.00 Cr.. The value appears strong and on an upward trend. It has increased from 137.00 Cr. (Jun 2025) to 193.00 Cr., marking an increase of 56.00 Cr..
- For Expenses, as of Sep 2025, the value is 162.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 122.00 Cr. (Jun 2025) to 162.00 Cr., marking an increase of 40.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 31.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Jun 2025) to 31.00 Cr., marking an increase of 16.00 Cr..
- For OPM %, as of Sep 2025, the value is 16.00%. The value appears strong and on an upward trend. It has increased from 11.00% (Jun 2025) to 16.00%, marking an increase of 5.00%.
- For Other Income, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Jun 2025) to 2.00 Cr., marking a decrease of 1.00 Cr..
- For Interest, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00 Cr..
- For Depreciation, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 6.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from 13.00 Cr. (Jun 2025) to 26.00 Cr., marking an increase of 13.00 Cr..
- For Tax %, as of Sep 2025, the value is 24.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 24.00%.
- For Net Profit, as of Sep 2025, the value is 20.00 Cr.. The value appears strong and on an upward trend. It has increased from 10.00 Cr. (Jun 2025) to 20.00 Cr., marking an increase of 10.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 15.06. The value appears strong and on an upward trend. It has increased from 7.18 (Jun 2025) to 15.06, marking an increase of 7.88.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:25 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 531 | 455 | 407 | 400 | 372 | 322 | 335 | 544 | 597 | 552 | 596 | 640 | 702 |
| Expenses | 393 | 366 | 326 | 349 | 333 | 289 | 295 | 490 | 535 | 492 | 537 | 577 | 608 |
| Operating Profit | 138 | 89 | 81 | 51 | 39 | 33 | 41 | 54 | 62 | 60 | 60 | 64 | 94 |
| OPM % | 26% | 20% | 20% | 13% | 11% | 10% | 12% | 10% | 10% | 11% | 10% | 10% | 13% |
| Other Income | 0 | 1 | 2 | 2 | 2 | -3 | -4 | 43 | 8 | 10 | 12 | 31 | 24 |
| Interest | 29 | 41 | 38 | 34 | 35 | 25 | 13 | 13 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 40 | 46 | 42 | 40 | 34 | 34 | 32 | 35 | 34 | 32 | 26 | 23 | 22 |
| Profit before tax | 69 | 3 | 4 | -22 | -28 | -30 | -8 | 49 | 36 | 38 | 45 | 72 | 95 |
| Tax % | 7% | -95% | 52% | -21% | 11% | -4% | 24% | -27% | -12% | 30% | 36% | 37% | |
| Net Profit | 64 | 5 | 2 | -17 | -31 | -29 | -10 | 62 | 41 | 27 | 28 | 45 | 70 |
| EPS in Rs | 56.20 | 4.51 | 1.49 | -13.84 | -24.87 | -23.15 | -8.10 | 50.05 | 30.46 | 19.88 | 21.31 | 33.90 | 52.61 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -92.19% | -60.00% | -950.00% | -82.35% | 6.45% | 65.52% | 720.00% | -33.87% | -34.15% | 3.70% | 60.71% |
| Change in YoY Net Profit Growth (%) | 0.00% | 32.19% | -890.00% | 867.65% | 88.80% | 59.07% | 654.48% | -753.87% | -0.28% | 37.85% | 57.01% |
Venus Remedies Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 14% |
| 3 Years: | 2% |
| TTM: | 9% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 22% |
| 5 Years: | 69% |
| 3 Years: | -3% |
| TTM: | 64% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 36% |
| 3 Years: | 30% |
| 1 Year: | 31% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 8% |
| 3 Years: | 6% |
| Last Year: | 7% |
Last Updated: September 5, 2025, 1:51 pm
Balance Sheet
Last Updated: December 4, 2025, 2:11 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 11 | 11 | 11 | 12 | 12 | 12 | 12 | 12 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 450 | 445 | 426 | 376 | 350 | 320 | 311 | 388 | 427 | 447 | 474 | 548 | 581 |
| Borrowings | 289 | 321 | 335 | 312 | 307 | 298 | 220 | 51 | 43 | 42 | 41 | 2 | 14 |
| Other Liabilities | 84 | 64 | 70 | 65 | 82 | 102 | 100 | 104 | 97 | 98 | 98 | 153 | 159 |
| Total Liabilities | 834 | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 768 |
| Fixed Assets | 439 | 444 | 452 | 406 | 389 | 364 | 289 | 262 | 241 | 216 | 219 | 229 | 237 |
| CWIP | 68 | 78 | 80 | 66 | 65 | 65 | 25 | 25 | 25 | 26 | 21 | 26 | 34 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 19 | 84 | 193 |
| Other Assets | 327 | 319 | 310 | 293 | 297 | 304 | 330 | 269 | 314 | 339 | 368 | 376 | 303 |
| Total Assets | 834 | 841 | 843 | 765 | 751 | 733 | 644 | 556 | 580 | 601 | 627 | 716 | 768 |
Below is a detailed analysis of the balance sheet data for Venus Remedies Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is 581.00 Cr.. The value appears strong and on an upward trend. It has increased from 548.00 Cr. (Mar 2025) to 581.00 Cr., marking an increase of 33.00 Cr..
- For Borrowings, as of Sep 2025, the value is 14.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2.00 Cr. (Mar 2025) to 14.00 Cr., marking an increase of 12.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 159.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 153.00 Cr. (Mar 2025) to 159.00 Cr., marking an increase of 6.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 768.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 716.00 Cr. (Mar 2025) to 768.00 Cr., marking an increase of 52.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 237.00 Cr.. The value appears strong and on an upward trend. It has increased from 229.00 Cr. (Mar 2025) to 237.00 Cr., marking an increase of 8.00 Cr..
- For CWIP, as of Sep 2025, the value is 34.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Mar 2025) to 34.00 Cr., marking an increase of 8.00 Cr..
- For Investments, as of Sep 2025, the value is 193.00 Cr.. The value appears strong and on an upward trend. It has increased from 84.00 Cr. (Mar 2025) to 193.00 Cr., marking an increase of 109.00 Cr..
- For Other Assets, as of Sep 2025, the value is 303.00 Cr.. The value appears to be declining and may need further review. It has decreased from 376.00 Cr. (Mar 2025) to 303.00 Cr., marking a decrease of 73.00 Cr..
- For Total Assets, as of Sep 2025, the value is 768.00 Cr.. The value appears strong and on an upward trend. It has increased from 716.00 Cr. (Mar 2025) to 768.00 Cr., marking an increase of 52.00 Cr..
Notably, the Reserves (581.00 Cr.) exceed the Borrowings (14.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -151.00 | -232.00 | -254.00 | -261.00 | -268.00 | -265.00 | -179.00 | 3.00 | 19.00 | 18.00 | 19.00 | 62.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 45 | 51 | 55 | 43 | 46 | 43 | 33 | 21 | 24 | 51 | 49 | 64 |
| Inventory Days | 173 | 194 | 219 | 226 | 246 | 286 | 296 | 129 | 118 | 132 | 125 | 97 |
| Days Payable | 38 | 40 | 38 | 48 | 52 | 72 | 77 | 76 | 47 | 56 | 55 | 89 |
| Cash Conversion Cycle | 180 | 204 | 236 | 221 | 240 | 257 | 252 | 74 | 95 | 127 | 120 | 72 |
| Working Capital Days | 39 | 54 | 69 | 54 | 25 | -1 | 73 | 71 | 82 | 109 | 118 | 86 |
| ROCE % | 14% | 6% | 5% | 2% | 1% | 1% | 2% | 8% | 8% | 8% | 9% | 11% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 33.90 | 21.31 | 19.88 | 30.86 | 50.04 |
| Diluted EPS (Rs.) | 33.90 | 21.31 | 19.88 | 30.86 | 50.04 |
| Cash EPS (Rs.) | 50.74 | 41.10 | 44.04 | 55.55 | 78.63 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 419.65 | 364.74 | 344.38 | 329.50 | 324.33 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 419.65 | 364.74 | 344.38 | 329.50 | 324.33 |
| Revenue From Operations / Share (Rs.) | 484.69 | 449.95 | 415.58 | 447.86 | 444.11 |
| PBDIT / Share (Rs.) | 63.20 | 53.25 | 52.76 | 52.68 | 59.48 |
| PBIT / Share (Rs.) | 46.37 | 33.47 | 28.60 | 27.60 | 30.90 |
| PBT / Share (Rs.) | 53.73 | 33.40 | 28.38 | 27.24 | 39.34 |
| Net Profit / Share (Rs.) | 33.90 | 21.31 | 19.87 | 30.47 | 50.04 |
| NP After MI And SOA / Share (Rs.) | 33.90 | 21.31 | 19.87 | 30.47 | 50.04 |
| PBDIT Margin (%) | 13.04 | 11.83 | 12.69 | 11.76 | 13.39 |
| PBIT Margin (%) | 9.56 | 7.43 | 6.88 | 6.16 | 6.95 |
| PBT Margin (%) | 11.08 | 7.42 | 6.82 | 6.08 | 8.85 |
| Net Profit Margin (%) | 6.99 | 4.73 | 4.78 | 6.80 | 11.26 |
| NP After MI And SOA Margin (%) | 6.99 | 4.73 | 4.78 | 6.80 | 11.26 |
| Return on Networth / Equity (%) | 8.07 | 5.84 | 5.77 | 9.24 | 15.43 |
| Return on Capital Employeed (%) | 10.69 | 8.17 | 7.37 | 7.57 | 8.31 |
| Return On Assets (%) | 6.33 | 4.54 | 4.41 | 7.02 | 11.11 |
| Long Term Debt / Equity (X) | 0.00 | 0.07 | 0.08 | 0.08 | 0.11 |
| Total Debt / Equity (X) | 0.00 | 0.08 | 0.09 | 0.09 | 0.12 |
| Asset Turnover Ratio (%) | 0.96 | 0.97 | 0.90 | 1.01 | 0.86 |
| Current Ratio (X) | 3.31 | 4.53 | 3.91 | 3.00 | 2.38 |
| Quick Ratio (X) | 2.58 | 2.99 | 2.46 | 1.64 | 1.15 |
| Inventory Turnover Ratio (X) | 5.83 | 2.85 | 2.65 | 3.04 | 2.64 |
| Interest Coverage Ratio (X) | 1291.82 | 759.66 | 239.55 | 146.41 | 5.64 |
| Interest Coverage Ratio (Post Tax) (X) | 542.31 | 305.06 | 91.24 | 85.67 | 3.94 |
| Enterprise Value (Cr.) | 322.06 | 409.53 | 205.06 | 351.82 | 361.07 |
| EV / Net Operating Revenue (X) | 0.49 | 0.68 | 0.36 | 0.58 | 0.65 |
| EV / EBITDA (X) | 3.81 | 5.75 | 2.91 | 5.00 | 4.92 |
| MarketCap / Net Operating Revenue (X) | 0.61 | 0.72 | 0.38 | 0.60 | 0.61 |
| Price / BV (X) | 0.71 | 0.89 | 0.47 | 0.81 | 0.84 |
| Price / Net Operating Revenue (X) | 0.61 | 0.72 | 0.38 | 0.60 | 0.61 |
| EarningsYield | 0.11 | 0.06 | 0.12 | 0.11 | 0.18 |
After reviewing the key financial ratios for Venus Remedies Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
- For Diluted EPS (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
- For Cash EPS (Rs.), as of Mar 25, the value is 50.74. This value is within the healthy range. It has increased from 41.10 (Mar 24) to 50.74, marking an increase of 9.64.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 419.65. It has increased from 364.74 (Mar 24) to 419.65, marking an increase of 54.91.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 419.65. It has increased from 364.74 (Mar 24) to 419.65, marking an increase of 54.91.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 484.69. It has increased from 449.95 (Mar 24) to 484.69, marking an increase of 34.74.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 63.20. This value is within the healthy range. It has increased from 53.25 (Mar 24) to 63.20, marking an increase of 9.95.
- For PBIT / Share (Rs.), as of Mar 25, the value is 46.37. This value is within the healthy range. It has increased from 33.47 (Mar 24) to 46.37, marking an increase of 12.90.
- For PBT / Share (Rs.), as of Mar 25, the value is 53.73. This value is within the healthy range. It has increased from 33.40 (Mar 24) to 53.73, marking an increase of 20.33.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 33.90. This value is within the healthy range. It has increased from 21.31 (Mar 24) to 33.90, marking an increase of 12.59.
- For PBDIT Margin (%), as of Mar 25, the value is 13.04. This value is within the healthy range. It has increased from 11.83 (Mar 24) to 13.04, marking an increase of 1.21.
- For PBIT Margin (%), as of Mar 25, the value is 9.56. This value is below the healthy minimum of 10. It has increased from 7.43 (Mar 24) to 9.56, marking an increase of 2.13.
- For PBT Margin (%), as of Mar 25, the value is 11.08. This value is within the healthy range. It has increased from 7.42 (Mar 24) to 11.08, marking an increase of 3.66.
- For Net Profit Margin (%), as of Mar 25, the value is 6.99. This value is within the healthy range. It has increased from 4.73 (Mar 24) to 6.99, marking an increase of 2.26.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 6.99. This value is below the healthy minimum of 8. It has increased from 4.73 (Mar 24) to 6.99, marking an increase of 2.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 8.07. This value is below the healthy minimum of 15. It has increased from 5.84 (Mar 24) to 8.07, marking an increase of 2.23.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.69. This value is within the healthy range. It has increased from 8.17 (Mar 24) to 10.69, marking an increase of 2.52.
- For Return On Assets (%), as of Mar 25, the value is 6.33. This value is within the healthy range. It has increased from 4.54 (Mar 24) to 6.33, marking an increase of 1.79.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. It has decreased from 0.07 (Mar 24) to 0.00, marking a decrease of 0.07.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.08 (Mar 24) to 0.00, marking a decrease of 0.08.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.96. It has decreased from 0.97 (Mar 24) to 0.96, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 3.31. This value exceeds the healthy maximum of 3. It has decreased from 4.53 (Mar 24) to 3.31, marking a decrease of 1.22.
- For Quick Ratio (X), as of Mar 25, the value is 2.58. This value exceeds the healthy maximum of 2. It has decreased from 2.99 (Mar 24) to 2.58, marking a decrease of 0.41.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.83. This value is within the healthy range. It has increased from 2.85 (Mar 24) to 5.83, marking an increase of 2.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1,291.82. This value is within the healthy range. It has increased from 759.66 (Mar 24) to 1,291.82, marking an increase of 532.16.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 542.31. This value is within the healthy range. It has increased from 305.06 (Mar 24) to 542.31, marking an increase of 237.25.
- For Enterprise Value (Cr.), as of Mar 25, the value is 322.06. It has decreased from 409.53 (Mar 24) to 322.06, marking a decrease of 87.47.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.49. This value is below the healthy minimum of 1. It has decreased from 0.68 (Mar 24) to 0.49, marking a decrease of 0.19.
- For EV / EBITDA (X), as of Mar 25, the value is 3.81. This value is below the healthy minimum of 5. It has decreased from 5.75 (Mar 24) to 3.81, marking a decrease of 1.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.72 (Mar 24) to 0.61, marking a decrease of 0.11.
- For Price / BV (X), as of Mar 25, the value is 0.71. This value is below the healthy minimum of 1. It has decreased from 0.89 (Mar 24) to 0.71, marking a decrease of 0.18.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 1. It has decreased from 0.72 (Mar 24) to 0.61, marking a decrease of 0.11.
- For EarningsYield, as of Mar 25, the value is 0.11. This value is below the healthy minimum of 5. It has increased from 0.06 (Mar 24) to 0.11, marking an increase of 0.05.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Venus Remedies Ltd:
- Net Profit Margin: 6.99%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.69% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 8.07% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 542.31
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.58
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 14.2 (Industry average Stock P/E: 46.53)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 6.99%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | S.C.O. 857, C. No. 10, 2nd Floor, NAC Manimajra, Chandigarh Chandigarh 160101 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Pawan Chaudhary | Chairman & Managing Director |
| Dr.(Mrs.) Manu Chaudhary | Joint Managing Director |
| Mr. Peeyush Jain | Deputy Managing Director |
| Mr. Ashutosh Jain | Executive Director |
| Mr. Akshansh Chaudhary | Executive Director |
| Dr.(Mrs.) Savita Gupta | Independent Director |
| Mr. N P S Monga | Independent Director |
| Mr. Navdeep Sud | Independent Director |
| Mr. Jagdish Chander Sharma | Independent Director |
| Dr. Anil Kumar | Independent Director |
FAQ
What is the intrinsic value of Venus Remedies Ltd?
Venus Remedies Ltd's intrinsic value (as of 01 February 2026) is ₹411.83 which is 49.34% lower the current market price of ₹813.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹1,087 Cr. market cap, FY2025-2026 high/low of ₹849/278, reserves of ₹581 Cr, and liabilities of ₹768 Cr.
What is the Market Cap of Venus Remedies Ltd?
The Market Cap of Venus Remedies Ltd is 1,087 Cr..
What is the current Stock Price of Venus Remedies Ltd as on 01 February 2026?
The current stock price of Venus Remedies Ltd as on 01 February 2026 is ₹813.
What is the High / Low of Venus Remedies Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Venus Remedies Ltd stocks is ₹849/278.
What is the Stock P/E of Venus Remedies Ltd?
The Stock P/E of Venus Remedies Ltd is 14.2.
What is the Book Value of Venus Remedies Ltd?
The Book Value of Venus Remedies Ltd is 445.
What is the Dividend Yield of Venus Remedies Ltd?
The Dividend Yield of Venus Remedies Ltd is 0.00 %.
What is the ROCE of Venus Remedies Ltd?
The ROCE of Venus Remedies Ltd is 11.1 %.
What is the ROE of Venus Remedies Ltd?
The ROE of Venus Remedies Ltd is 7.16 %.
What is the Face Value of Venus Remedies Ltd?
The Face Value of Venus Remedies Ltd is 10.0.